Susquehanna Fundamental Investments LLC Purchases Shares of 210,468 The Chemours Company (NYSE:CC)

Susquehanna Fundamental Investments LLC bought a new stake in The Chemours Company (NYSE:CC - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 210,468 shares of the specialty chemicals company's stock, valued at approximately $3,557,000. Susquehanna Fundamental Investments LLC owned about 0.14% of Chemours at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GAMMA Investing LLC lifted its holdings in shares of Chemours by 99.7% in the 4th quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company's stock valued at $26,000 after purchasing an additional 765 shares during the last quarter. Quadrant Capital Group LLC grew its position in shares of Chemours by 100.4% during the fourth quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company's stock worth $38,000 after acquiring an additional 1,119 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new position in shares of Chemours in the 4th quarter valued at $48,000. KBC Group NV raised its position in Chemours by 38.2% in the 4th quarter. KBC Group NV now owns 6,176 shares of the specialty chemicals company's stock valued at $104,000 after purchasing an additional 1,708 shares during the last quarter. Finally, Sterling Capital Management LLC boosted its stake in Chemours by 54.8% during the 4th quarter. Sterling Capital Management LLC now owns 8,453 shares of the specialty chemicals company's stock worth $143,000 after purchasing an additional 2,991 shares during the period. 76.26% of the stock is owned by hedge funds and other institutional investors.

Chemours Price Performance

Chemours stock traded up $0.27 during trading hours on Friday, hitting $12.47. The stock had a trading volume of 1,885,956 shares, compared to its average volume of 1,877,656. The Chemours Company has a 1-year low of $9.33 and a 1-year high of $29.21. The stock has a market capitalization of $1.86 billion, a price-to-earnings ratio of 21.88 and a beta of 1.84. The stock's fifty day moving average is $12.94 and its two-hundred day moving average is $16.86. The company has a debt-to-equity ratio of 6.70, a current ratio of 1.68 and a quick ratio of 0.92.

Chemours (NYSE:CC - Get Free Report) last issued its quarterly earnings data on Tuesday, February 18th. The specialty chemicals company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $0.01. The firm had revenue of $1.36 billion for the quarter, compared to analysts' expectations of $1.37 billion. Chemours had a net margin of 1.51% and a return on equity of 26.54%. As a group, analysts predict that The Chemours Company will post 2.03 earnings per share for the current fiscal year.

Chemours Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Friday, February 28th were issued a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 8.02%. The ex-dividend date was Friday, February 28th. Chemours's dividend payout ratio (DPR) is presently 175.44%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on CC. Truist Financial decreased their target price on shares of Chemours from $27.00 to $22.00 and set a "buy" rating for the company in a research note on Monday, April 14th. The Goldman Sachs Group dropped their target price on Chemours from $24.00 to $21.00 and set a "neutral" rating on the stock in a report on Tuesday, January 7th. BMO Capital Markets lowered their price objective on shares of Chemours from $34.00 to $27.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 19th. Barclays reduced their target price on shares of Chemours from $19.00 to $16.00 and set an "equal weight" rating for the company in a research note on Tuesday, April 1st. Finally, Mizuho set a $15.00 price target on shares of Chemours in a report on Tuesday, April 15th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, Chemours has a consensus rating of "Moderate Buy" and an average target price of $21.56.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.